…if it is ultimately proven that TEVA infringed on MNTA's patents, if the FDA approves tEnox, MNTA's cash flow will be dramatically impacted until there is a ruling.That’s not true—a step-down in MNTA’s cash flow occurs only if a competing generic Lovenox is commercially launched.